Procyon Corporation Stock

Equities

PCYN

US7428063009

Pharmaceuticals

Market Closed - OTC Markets 03:38:32 2024-06-03 pm EDT 5-day change 1st Jan Change
0.2532 USD +26.62% Intraday chart for Procyon Corporation +20.91% +48.56%
Sales 2022 4.84M Sales 2023 4.69M Capitalization 2.02M
Net income 2022 - Net income 2023 - EV / Sales 2022 0.71 x
Net cash position 2022 347K Net cash position 2023 427K EV / Sales 2023 0.34 x
P/E ratio 2022
-15.7 x
P/E ratio 2023
-25 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 34.54%
More Fundamentals * Assessed data
Dynamic Chart
Procyon Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Procyon Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Procyon Corporation Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Procyon Corporation Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Procyon Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Procyon Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Procyon Corporation Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Procyon Corporation Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Procyon Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022 CI
Procyon Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021 CI
Procyon Corporation Reports Earnings Results for the First Quarter Ended September 30, 2021 CI
Procyon Corporation Reports Earnings Results for the Full Year Ended June 30, 2021 CI
Procyon Corporation Announces Board Changes CI
Procyon Corporation Announces Resignation of Paul E. Kudelko, Sr. as Board of Directors CI
Procyon Corporation Reports Earnings Results for the Third Quarter Ended March 31, 2021 CI
More news
1 day+26.63%
1 week+20.91%
Current month+26.65%
1 month+15.93%
3 months-15.00%
6 months+68.87%
Current year+48.56%
More quotes
1 week
0.22
Extreme 0.224869
0.25
1 month
0.20
Extreme 0.2
0.25
Current year
0.17
Extreme 0.17
0.30
1 year
0.15
Extreme 0.1488
0.30
3 years
0.15
Extreme 0.1488
0.64
5 years
0.15
Extreme 0.1488
1.00
10 years
0.07
Extreme 0.0651
1.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 05-12-31
Chairman 77 05-08-31
Director of Finance/CFO 54 95-12-31
Members of the board TitleAgeSince
Chief Executive Officer 47 05-12-31
Director of Finance/CFO 54 95-12-31
Chairman 77 05-08-31
More insiders
Date Price Change Volume
24-06-03 0.2532 +26.62% 3,479

Delayed Quote OTC Markets, June 03, 2024 at 03:38 pm EDT

More quotes
Procyon Corporation operates through its subsidiaries AMERX Health Care Corporation (AMERX) and Sirius Medical Supply, Inc. (Sirius). AMERX develops and markets proprietary medical products used in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation and other skin problems. Its product lines include AMERX, AMERIGEL, HELIX3 Bioactive Collagen, EXTREMIT-EASE Compression Garment and Advantagen Surgical Collagen. AMERX markets a line of AMERIGEL advanced skin and wound care products made with Oakin, that promote healing in wound and problematic skin conditions, including AMERIGEL Hydrogel Wound Dressing, AMERIGEL Post Op Surgical Kits, AMERIGEL Saline Wound Wash, AMERIGEL Care Lotion, and AMERIGEL Barrier Lotion. HELIX3 is available in Collagen Powder and Collagen Matrix. Its wound care product includes AMERX Calcium Alginate Dressing, AMERX Foam Dressing, AMERX Gauze Dressing, AMERX Hyrdocolloid Dressing, and AMERX Wound Care Kits.
More about the company